Use of Rapamycin in a Patient With Juvenile Myelomonocytic Leukemia: A Case Report

The relapse rate for children with juvenile myelomonocytic leukemia (JMML) status post hematopoietic stem cell transplantation (HSCT) approaches 50% within 5 years. Graft-versus-leukemia (GVL) is thought to play important role in the treatment of JMML. For this reason, careful management of immunosu...

Descripción completa

Detalles Bibliográficos
Autores principales: Upadhyay, Shivani Y., De Oliveira, Satiro N., Moore, Theodore B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593212/
https://www.ncbi.nlm.nih.gov/pubmed/28959694
http://dx.doi.org/10.1177/2324709617728528
_version_ 1783263010494611456
author Upadhyay, Shivani Y.
De Oliveira, Satiro N.
Moore, Theodore B.
author_facet Upadhyay, Shivani Y.
De Oliveira, Satiro N.
Moore, Theodore B.
author_sort Upadhyay, Shivani Y.
collection PubMed
description The relapse rate for children with juvenile myelomonocytic leukemia (JMML) status post hematopoietic stem cell transplantation (HSCT) approaches 50% within 5 years. Graft-versus-leukemia (GVL) is thought to play important role in the treatment of JMML. For this reason, careful management of immunosuppressive drugs after HSCT is crucial. This case report demonstrates that rapamycin and GVL represent a viable medical strategy for the management of pediatric patients with JMML who relapse following status post-HSCT.
format Online
Article
Text
id pubmed-5593212
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-55932122017-09-28 Use of Rapamycin in a Patient With Juvenile Myelomonocytic Leukemia: A Case Report Upadhyay, Shivani Y. De Oliveira, Satiro N. Moore, Theodore B. J Investig Med High Impact Case Rep Case Report The relapse rate for children with juvenile myelomonocytic leukemia (JMML) status post hematopoietic stem cell transplantation (HSCT) approaches 50% within 5 years. Graft-versus-leukemia (GVL) is thought to play important role in the treatment of JMML. For this reason, careful management of immunosuppressive drugs after HSCT is crucial. This case report demonstrates that rapamycin and GVL represent a viable medical strategy for the management of pediatric patients with JMML who relapse following status post-HSCT. SAGE Publications 2017-09-08 /pmc/articles/PMC5593212/ /pubmed/28959694 http://dx.doi.org/10.1177/2324709617728528 Text en © 2017 American Federation for Medical Research http://creativecommons.org/licenses/by/4.0/ This article is distributed under the terms of the Creative Commons Attribution 4.0 License (http://www.creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Case Report
Upadhyay, Shivani Y.
De Oliveira, Satiro N.
Moore, Theodore B.
Use of Rapamycin in a Patient With Juvenile Myelomonocytic Leukemia: A Case Report
title Use of Rapamycin in a Patient With Juvenile Myelomonocytic Leukemia: A Case Report
title_full Use of Rapamycin in a Patient With Juvenile Myelomonocytic Leukemia: A Case Report
title_fullStr Use of Rapamycin in a Patient With Juvenile Myelomonocytic Leukemia: A Case Report
title_full_unstemmed Use of Rapamycin in a Patient With Juvenile Myelomonocytic Leukemia: A Case Report
title_short Use of Rapamycin in a Patient With Juvenile Myelomonocytic Leukemia: A Case Report
title_sort use of rapamycin in a patient with juvenile myelomonocytic leukemia: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593212/
https://www.ncbi.nlm.nih.gov/pubmed/28959694
http://dx.doi.org/10.1177/2324709617728528
work_keys_str_mv AT upadhyayshivaniy useofrapamycininapatientwithjuvenilemyelomonocyticleukemiaacasereport
AT deoliveirasatiron useofrapamycininapatientwithjuvenilemyelomonocyticleukemiaacasereport
AT mooretheodoreb useofrapamycininapatientwithjuvenilemyelomonocyticleukemiaacasereport

Ejemplares similares